SCHEMBL3762073

SCHEMBL3762073

CC(C)(C)OC(=O)C(C(=O)NCN1CCCC1)c1cc[c]cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.33
ACHE P22303 2/20 0.33
BACE1 P56817 1/20 0.33
RAB9A P51151 3/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
BCL3 P20749 1/20 0.32
KMT2A Q03164 2/20 0.32
LMNA P02545 1/20 0.32
NPC1 O15118 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
POLB P06746 1/20 0.32
MEN1 O00255 1/20 0.31
BCHE P06276 1/20 0.31
KDM4E B2RXH2 2/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762071 0.81 MEN1 (0.36) RAB9ABCL3KMT2AMEN1KDM4E
SCHEMBL2748201 0.68 L3MBTL1 (0.46) ACHEBACE1CTSKKMT2AALDH1A1
SCHEMBL1019116 0.66 EPHX1 (0.45) ACHEBACE1CTSKKMT2AALDH1A1
Hydrochloric Acid SCHEMBL3564514 0.65 EPHX1 (0.44) ACHEBACE1CTSKKMT2AALDH1A1
SCHEMBL501866 0.65 LMNA (0.36) RAB9ACTSSCTSKKMT2ALMNA
SCHEMBL16161887 0.65 CTSL (0.42) HRH3LMNAMAPT
SCHEMBL3759223 0.65 GAA (0.49) RAB9ABCL3KMT2ANPC1ALDH1A1
SCHEMBL1398635 0.65 NPSR1 (0.44) CTSKKMT2AALDH1A1L3MBTL1MEN1
SCHEMBL3265270 0.63 CTSK (0.34) CTSKKMT2AALDH1A1MAPTMEN1
SCHEMBL3265268 0.63 CTSK (0.34) CTSKKMT2AALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA HRH3 1432/4885ACHE 848/4885BACE1 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.